MiNK Therapeutics Initiates Phase 1 Clinical Trial for agenT-797
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Should l Buy INKT?
MiNK Therapeutics announced the upcoming initiation of a Phase 1, investigator-sponsored clinical trial evaluating its lead therapy, agenT-797, in patients undergoing allogeneic hematopoietic stem cell transplantation. The trial, led by Hongtao Liu, Associate Professor of Medicine, University of Wisconsin School of Medicine and Public Health, with co-investigator Kalyan Nadiminti, Assistant Professor of Medicine at the University of Wisconsin School of Medicine and Public Health, will evaluate the safety, tolerability, and preliminary efficacy of agenT-797 in reducing graft-versus-host disease, relapse, and other post-transplant complications in patients with high-risk leukemias and other blood cancers. Two complementary public-private funding awards support the advancement of agenT-797 development in HSCT and GvHD. First, an NIH STTR grant from the National Institute of Allergy and Infectious Diseases supports MiNK and the University of Wisconsin-Madison team to develop and evaluate agenT-797 in preclinical models. Second, a philanthropic clinical grant, the Mary Gooze Clinical Trial Award to the University of Wisconsin-Madison directly funds enrollment, immune monitoring, and operations for the Phase 1. Together, these awards enable the simultaneous execution of translational and clinical studies of iNKTs in GvHD prevention.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INKT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INKT
Wall Street analysts forecast INKT stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 14.210
Low
35.00
Averages
35.00
High
35.00
Current: 14.210
Low
35.00
Averages
35.00
High
35.00
About INKT
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MiNK Therapeutics Reports Promising Results in Gastroesophageal Cancer Study
- Clinical Trial Results: MiNK Therapeutics' Phase II trial for PD-1 refractory gastroesophageal cancer demonstrated a 77% disease control rate (DCR) using a combination of agenT-797, botensilimab, and balstilimab, with some patients surviving beyond 20 months, indicating the therapy's potential.
- Survival Improvement: Patients receiving induction therapy had a median progression-free survival (PFS) of 6.9 months compared to 3.5 months for those without induction (HR 0.19; p=0.015), highlighting the significant impact of immune activation and treatment sequencing on survival.
- Long-term Survival Rates: Among induction-treated patients, 43% were alive at 12 and 18 months, while only 20% and 0% of non-induction patients survived, underscoring the importance of induction therapy in enhancing survival rates.
- Immune Mechanism Analysis: The study revealed significant intratumoral T cell and dendritic cell infiltration, along with organized lymphoid structures in biopsies, further supporting agenT-797's role as an immune orchestrator and potentially guiding future treatment strategies.
See More
MiNK Therapeutics Unveils New Data on iNKT Cell Therapy
- Clinical Trial Progress: MiNK Therapeutics will present data from its Phase II trial at Memorial Sloan Kettering Cancer Center on April 20, 2026, evaluating the allo-iNKT cell therapy agenT-797 in combination with dual checkpoint inhibitors BOT and BAL for PD-1 refractory gastroesophageal cancer, addressing a significant clinical need in this area.
- Immune Modulation Potential: This study represents one of the first clinical evaluations of combining iNKT cell therapy with dual checkpoint modulation, potentially providing crucial insights into re-engaging the immune system in patients who have progressed on prior checkpoint therapies, thereby driving more durable treatment outcomes.
- Innovative Treatment Strategy: As an immune orchestrator, agenT-797 is designed to reprogram the tumor microenvironment and restore immune responsiveness, which is expected to inform new treatment sequencing strategies for refractory cancers and advance the next generation of combination therapies.
- Future Outlook: MiNK Therapeutics is committed to developing next-generation immune reconstitution therapies, with agenT-797's clinical development targeting not only GVHD and solid tumors but also potentially improving inflammatory responses in critically ill patients, showcasing its broad therapeutic potential.
See More
MiNK Therapeutics' iNKT Cell Therapy Accepted for ASGCT Presentation
- Conference Presentation: MiNK Therapeutics announced that its investigational iNKT cell therapy, agenT-797, has been accepted for presentation at the ASGCT Annual Meeting, showcasing its potential for adaptive immune modulation in cancer and immune-mediated diseases, which is expected to enhance the company's visibility in the biopharmaceutical sector.
- Speaker Credentials: The presentation will be led by Dr. Terese C. Hammond, who serves as the Program Director of Pulmonary and Critical Care at Kaweah Health Medical Center and Head of Inflammatory and Pulmonary Diseases at MiNK, highlighting the company's leadership in the field.
- Clinical Development Progress: AgenT-797, an allogeneic iNKT cell therapy, is currently in clinical development for GVHD, solid tumors, and severe pulmonary inflammation, demonstrating its potential to provide new treatment options for patients with hard-to-treat tumors.
- Technological Advantages: This therapy harnesses the dual power of innate and adaptive immunity, capable of activating peripheral memory T cells and enhancing tumor infiltration, which is anticipated to improve outcomes for patients with solid cancers, further solidifying MiNK's market position in immune reconstitution therapies.
See More
MiNK Therapeutics' iNKT Cell Therapy Accepted for ATS Conference Presentation
- Conference Presentation Opportunity: MiNK Therapeutics announced that its iNKT cell therapy, agenT-797, has been accepted for presentation at the 2026 ATS International Conference, scheduled for May 20, 2026, highlighting the company's ongoing innovation and influence in the immunotherapy field.
- Research Highlights: The abstract titled 'Novel Interleukin-15 Superagonist (N-803) and Invariant Natural Killer T Cell (agenT-797) Combination Immunotherapy' emphasizes a novel combination approach for immune activation and restoration in severe and persistent infections, showcasing its potential in treating complex diseases.
- Clinical Development Progress: As an allogeneic iNKT cell therapy, agenT-797 aims to improve outcomes for solid tumor patients by enhancing peripheral memory T-cell activation and tumor infiltration, reflecting MiNK's leading position in the cell therapy sector.
- Future Development Outlook: MiNK Therapeutics is committed to developing next-generation immune reconstitution therapies, with agenT-797's scalable cryopreserved manufacturing process providing broad treatment options, indicating the company's long-term growth potential in the biopharmaceutical industry.
See More
MiNK Therapeutics Financial and Clinical Progress Update
- Cash Flow Improvement: MiNK Therapeutics increased its cash balance to $13.4 million from $4.6 million, despite reporting a net loss of $12.5 million for 2025, indicating some effectiveness in financial management while still facing ongoing financial pressures.
- Clinical Trial Progress: The company has advanced its allogeneic invariant natural killer T cell platform into Phase 2 clinical trials for solid tumors and autoimmune inflammatory conditions, demonstrating durable survival and complete remission in heavily pretreated cancer patients, although uncertainties in clinical development remain.
- Significant Cost Control: Operating costs decreased by nearly 40% year-over-year, which not only enhances capital efficiency but also provides more funding support for future clinical trials and R&D, despite potential clinical and regulatory risks that need to be monitored.
- External Funding Support: The company raised an additional $3 million post-year-end through an at-the-market facility, further strengthening its financial position to support clinical trials in graft versus host disease and gastric cancer, with results expected to be presented at a major conference in the first half of the year.
See More
MiNK Therapeutics Q4 2025 Earnings Call Insights
- Clinical Activity Performance: MiNK Therapeutics reported in Q4 2025 that patients in its solid tumor program, when combined with PD-1 therapies, achieved a median overall survival exceeding 23 months and complete remissions lasting over 2 years, demonstrating the clinical efficacy and safety of its iNKT platform, which could enhance future market recognition.
- Improved Financial Position: CFO Melissa Orilall reported a cash balance of $13.4 million in Q4 2025, significantly up from $4.6 million year-over-year, and raised an additional $3 million through market financing, ensuring operational funding through 2026 to support key clinical milestones.
- Clinical Trial Progress: The company plans to initiate the first patient dosing in its randomized Phase II study for ARDS at top centers in Ukraine and the U.S., with initial clinical data expected in the second half of this year, indicating positive advancements in addressing acute respiratory distress syndrome.
- Strategic Investment Focus: Management emphasized non-dilutive funding and partnerships as a core operational model, particularly for the GvHD study, having secured external funding to advance MiNK cells into clinical trials, reflecting the company's commitment to future market opportunities.
See More
MiNK Therapeutics Reports Promising Results in Gastroesophageal Cancer Study
- Clinical Trial Results: MiNK Therapeutics' Phase II trial for PD-1 refractory gastroesophageal cancer demonstrated a 77% disease control rate (DCR) using a combination of agenT-797, botensilimab, and balstilimab, with some patients surviving beyond 20 months, indicating the therapy's potential.
- Survival Improvement: Patients receiving induction therapy had a median progression-free survival (PFS) of 6.9 months compared to 3.5 months for those without induction (HR 0.19; p=0.015), highlighting the significant impact of immune activation and treatment sequencing on survival.
- Long-term Survival Rates: Among induction-treated patients, 43% were alive at 12 and 18 months, while only 20% and 0% of non-induction patients survived, underscoring the importance of induction therapy in enhancing survival rates.
- Immune Mechanism Analysis: The study revealed significant intratumoral T cell and dendritic cell infiltration, along with organized lymphoid structures in biopsies, further supporting agenT-797's role as an immune orchestrator and potentially guiding future treatment strategies.
See More
MiNK Therapeutics Unveils New Data on iNKT Cell Therapy
- Clinical Trial Progress: MiNK Therapeutics will present data from its Phase II trial at Memorial Sloan Kettering Cancer Center on April 20, 2026, evaluating the allo-iNKT cell therapy agenT-797 in combination with dual checkpoint inhibitors BOT and BAL for PD-1 refractory gastroesophageal cancer, addressing a significant clinical need in this area.
- Immune Modulation Potential: This study represents one of the first clinical evaluations of combining iNKT cell therapy with dual checkpoint modulation, potentially providing crucial insights into re-engaging the immune system in patients who have progressed on prior checkpoint therapies, thereby driving more durable treatment outcomes.
- Innovative Treatment Strategy: As an immune orchestrator, agenT-797 is designed to reprogram the tumor microenvironment and restore immune responsiveness, which is expected to inform new treatment sequencing strategies for refractory cancers and advance the next generation of combination therapies.
- Future Outlook: MiNK Therapeutics is committed to developing next-generation immune reconstitution therapies, with agenT-797's clinical development targeting not only GVHD and solid tumors but also potentially improving inflammatory responses in critically ill patients, showcasing its broad therapeutic potential.
See More
MiNK Therapeutics' iNKT Cell Therapy Accepted for ASGCT Presentation
- Conference Presentation: MiNK Therapeutics announced that its investigational iNKT cell therapy, agenT-797, has been accepted for presentation at the ASGCT Annual Meeting, showcasing its potential for adaptive immune modulation in cancer and immune-mediated diseases, which is expected to enhance the company's visibility in the biopharmaceutical sector.
- Speaker Credentials: The presentation will be led by Dr. Terese C. Hammond, who serves as the Program Director of Pulmonary and Critical Care at Kaweah Health Medical Center and Head of Inflammatory and Pulmonary Diseases at MiNK, highlighting the company's leadership in the field.
- Clinical Development Progress: AgenT-797, an allogeneic iNKT cell therapy, is currently in clinical development for GVHD, solid tumors, and severe pulmonary inflammation, demonstrating its potential to provide new treatment options for patients with hard-to-treat tumors.
- Technological Advantages: This therapy harnesses the dual power of innate and adaptive immunity, capable of activating peripheral memory T cells and enhancing tumor infiltration, which is anticipated to improve outcomes for patients with solid cancers, further solidifying MiNK's market position in immune reconstitution therapies.
See More
MiNK Therapeutics' iNKT Cell Therapy Accepted for ATS Conference Presentation
- Conference Presentation Opportunity: MiNK Therapeutics announced that its iNKT cell therapy, agenT-797, has been accepted for presentation at the 2026 ATS International Conference, scheduled for May 20, 2026, highlighting the company's ongoing innovation and influence in the immunotherapy field.
- Research Highlights: The abstract titled 'Novel Interleukin-15 Superagonist (N-803) and Invariant Natural Killer T Cell (agenT-797) Combination Immunotherapy' emphasizes a novel combination approach for immune activation and restoration in severe and persistent infections, showcasing its potential in treating complex diseases.
- Clinical Development Progress: As an allogeneic iNKT cell therapy, agenT-797 aims to improve outcomes for solid tumor patients by enhancing peripheral memory T-cell activation and tumor infiltration, reflecting MiNK's leading position in the cell therapy sector.
- Future Development Outlook: MiNK Therapeutics is committed to developing next-generation immune reconstitution therapies, with agenT-797's scalable cryopreserved manufacturing process providing broad treatment options, indicating the company's long-term growth potential in the biopharmaceutical industry.
See More
MiNK Therapeutics Financial and Clinical Progress Update
- Cash Flow Improvement: MiNK Therapeutics increased its cash balance to $13.4 million from $4.6 million, despite reporting a net loss of $12.5 million for 2025, indicating some effectiveness in financial management while still facing ongoing financial pressures.
- Clinical Trial Progress: The company has advanced its allogeneic invariant natural killer T cell platform into Phase 2 clinical trials for solid tumors and autoimmune inflammatory conditions, demonstrating durable survival and complete remission in heavily pretreated cancer patients, although uncertainties in clinical development remain.
- Significant Cost Control: Operating costs decreased by nearly 40% year-over-year, which not only enhances capital efficiency but also provides more funding support for future clinical trials and R&D, despite potential clinical and regulatory risks that need to be monitored.
- External Funding Support: The company raised an additional $3 million post-year-end through an at-the-market facility, further strengthening its financial position to support clinical trials in graft versus host disease and gastric cancer, with results expected to be presented at a major conference in the first half of the year.
See More
MiNK Therapeutics Q4 2025 Earnings Call Insights
- Clinical Activity Performance: MiNK Therapeutics reported in Q4 2025 that patients in its solid tumor program, when combined with PD-1 therapies, achieved a median overall survival exceeding 23 months and complete remissions lasting over 2 years, demonstrating the clinical efficacy and safety of its iNKT platform, which could enhance future market recognition.
- Improved Financial Position: CFO Melissa Orilall reported a cash balance of $13.4 million in Q4 2025, significantly up from $4.6 million year-over-year, and raised an additional $3 million through market financing, ensuring operational funding through 2026 to support key clinical milestones.
- Clinical Trial Progress: The company plans to initiate the first patient dosing in its randomized Phase II study for ARDS at top centers in Ukraine and the U.S., with initial clinical data expected in the second half of this year, indicating positive advancements in addressing acute respiratory distress syndrome.
- Strategic Investment Focus: Management emphasized non-dilutive funding and partnerships as a core operational model, particularly for the GvHD study, having secured external funding to advance MiNK cells into clinical trials, reflecting the company's commitment to future market opportunities.
See More
